Herantis Pharma Plc.: Clinical Trials

8 trials sponsored by Herantis Pharma Plc., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 terminated, 1 unknown. 6 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Completed 4, Terminated 1, Unknown 1
Phase 25Completed 4, Unknown 1

Follow Herantis Pharma Plc.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease
HER-096, Placebo - Parkinson Disease, Idiopathic
Phase 1CompletedHerantis Pharma Plc.322024-09-232025-09-12
Single Ascending Doses of HER-096 in Healthy Subjects
HER-096, Placebo - Parkinson Disease
Phase 1CompletedHerantis Pharma Plc.602023-03-292023-10-27
Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions
Renishaw Drug Delivery System - Parkinson Disease, Movement Disorders
Phase 1 / Phase 2UnknownRenishaw152019-03-202021-03-23
Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study
Cerebral Dopamine Neurotrophic Factor, Renishaw Drug Delivery System - Parkinson Disease, Movement Disorders
Phase 1 / Phase 2CompletedHerantis Pharma Plc.152018-07-052020-08-12
Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE)
Lymfactin® (1x10E11 vp), Placebo - Secondary Lymphedema
Phase 2CompletedHerantis Pharma Plc.392018-06-072025-07-09
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
Cerebral Dopamine Neurotrophic Factor, Renishaw Drug Delivery System - Parkinson Disease, Movement Disorders
Phase 1 / Phase 2CompletedHerantis Pharma Plc.172017-09-262020-01-13
A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema
Lymfactin® [1 x 10E10 vp], Lymfactin® [1 x 10E11 vp] - Secondary Lymphedema
Phase 1TerminatedHerantis Pharma Plc.152016-06-012023-04-24
Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye
cis-UCA ophthalmic solution 1.0%, cis-UCA ophthalmic solution 2.5%, Placebo ophthalmic solution - Dry Eye Syndrome
Phase 2CompletedHerantis Pharma Plc.1612014-12-012015-09-09

Conditions studied

Parkinson Disease (5)  ·  Brain Diseases (3)  ·  Movement Disorders (3)  ·  Nervous System Diseases (3)  ·  Neurodegenerative Diseases (3)  ·  Central Nervous System Diseases (2)  ·  Basal Ganglia Diseases (1)  ·  Breast Cancer Lymphedema (1)  ·  Breast Neoplasms (1)  ·  Dry Eye Syndromes (1)  ·  Lymphedema (1)  ·  Parkinsonian Disorders (1)

Interventions

Sodium Chloride (2)

Countries

Finland (7)  ·  Sweden (4)  ·  United States (1)

Top investigators

Anne Saarikko, MD, PhD (2)  ·  Aleksi Tornio, MD (1)  ·  Maria Mani, MD, PhD (1)  ·  Per Svenningsson, MD (1)  ·  Per Svenningsson, MD, Prof. (1)  ·  Prof. Juha Rinne, MD, PhD (1)

Results publications

PMID 38072889, PMID 41173769

NIH funding

2015 (1), 2017 (1)